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Abstract
In this paper we determined the pharmacological profiles of novel ketamine and phencyclidine analogues currently used as
‘designer drugs’ and compared them to the parent substances via the resources of the National Institute of Mental Health
Psychoactive Drug Screening Program. The ketamine analogues methoxetamine ((RS)-2-(ethylamino)-2-(3-methoxyphe-
nyl)cyclohexanone) and 3-MeO-PCE (N-ethyl-1-(3-methoxyphenyl)cyclohexanamine) and the 3- and 4-methoxy analogues of
phencyclidine, (1-[1-(3-methoxyphenyl)cyclohexyl]piperidine and 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine), were all
high affinity ligands for the PCP-site on the glutamate NMDA receptor. In addition methoxetamine and PCP and its
analogues displayed appreciable affinities for the serotonin transporter, whilst the PCP analogues exhibited high affinities
for sigma receptors. Antagonism of the NMDA receptor is thought to be the key pharmacological feature underlying the
actions of dissociative anaesthetics. The novel ketamine and PCP analogues had significant affinities for the NMDA receptor
in radioligand binding assays, which may explain their psychotomimetic effects in human users. Additional actions on other
targets could be important for delineating side-effects.
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Introduction
The recent emergence of novel synthetic psychoactive drugs
and their sale through internet sites has raised concerns about the
potential harms associated with compounds which lack any formal
toxicology profiles [1–2]. Among the novel psychoactive substanc-
es that have emerged in recent years are methoxetamine ((RS)-2-
(ethylamino)-2-(3-methoxyphenyl)cyclohexanone), which is an
analogue of ketamine ((RS)-2-(2-chlorophenyl)-2-(methylamino)cy-
clohexanone), methoxetamine’s close deoxy-analogue 3-methox-
yeticyclidine (‘3-MeO-PCE’, N-ethyl-1-(3-methoxyphenyl)cyclo-
hexanamine), and both the 3- and 4-methoxy analogues of
phencyclidine, namely 1-[1-(3-methoxyphenyl)cyclohexyl]piperi-
dine and 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine (Figure 1).
Methoxetamine, also known as ‘MXE’, ‘MXE-powder’, ‘METH-
O’, and ‘MEXXY’ has gained some prominence in the United
Kingdom as a legal alternative to ketamine [1] [3]. Phencyclidine
(PCP) and the related compounds eticyclidine (PCE), rolicyclidine
and tenocyclidine are controlled substances, but recently 3-
methoxy-PCP, 4-methoxy-PCP, and 3-methoxy-PCE have
emerged as legally available alternatives to PCP [4].
Pharmacologically, ketamine’s main action is on glutamatergic
transmission, the major excitatory neurotransmitter system in the
brain. It is a non-competitive antagonist at one of the three
glutamate receptor subtypes, the N-methyl-D-aspartate (NMDA)
receptor [5]. The NMDA receptor is also considered to be a key
pharmacological target for phencyclidine [6–7]. Although there is
little information available on the novel ketamine and PCP
analogues, their behavioural effects in human subjects resemble
those induced by ketamine and PCP, characteristic of dissociative
anaesthetics [1]. The wanted effects include euphoria, empathy,
dissociation from the physical body, hallucinations, but these may
be accompanied by adverse side effects, dizziness, confusion,
psychomotor agitation, and cognitive impairment. The clinically
reported symptoms of acute toxicology of methoxetamine include
a ‘dissociative catatonic’ state similar to that seen with ketamine,
accompanied by sympathomimetic toxicity, with significant
tachycardia and hypertension [8–9]. Reversible cerebellar toxicity
has also been reported in three cases of methoxetamine overdose
[10]. A major physical harm associated with chronic ketamine use
is ulcerative cystitis, leading to significant damage to bladder
function, and evidence of dependence [5], but it is not yet known
whether methoxetamine will also prove to be associated with these
adverse side effects.
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In the present study the resources of the National Institute of
Mental Health Psychoactive Drug Screening Program (NIMH-
PDSP) were used to obtain neurochemical profiles of methox-
etamine and the novel PCP analogues and to compare these with
those of ketamine and PCP and other reference compounds. The
results confirmed that all of the novel analogues had significant
affinity for NMDA receptors, and revealed other effects possibly
mediated by monoamine transporter targets and sigma receptors.
Materials and Methods
Compounds
Samples of methoxetamine hydrochloride ((RS)-2-ethylamino-2-
(3-methoxyphenyl)cyclohexanone HCl), 3-methoxyphencyclidine
hydrochloride (3-MeO-PCP; 1-[1-(3-methoxyphenyl)cyclohexyl]-
piperidine HCl), and 3-methoxyeticyclidine hydrochloride (3-
MeO-PCE; N-ethyl-1-(3-methoxyphenyl)cyclohexanamine HCl)
were provided by LGC Standards (www.lgcstandards.com).
Chemical identity of these materials was established using proton
Nuclear Magnetic Resonance, Mass Spectrometry and Infrared
Spectroscopy. Purities were established using High Performance
Liquid Chromatography with Diode Array Detection, and
corrected for any residual water (by Karl Fischer) and residual
solvent (by proton NMR). Certified purities were 98.3%
(methoxetamine), 99.1% (3-methoxy-PCP) and 99.0% (3-me-
thoxy-PCE)1.
4-Methoxyphencyclidine (4-MeO-PCP; 1-[1-(4-methoxyphe-
nyl)cyclohexyl]piperidine) was purchased from a UK-based
website (Mandala supplies). The chemical identity was confirmed
by 1- and 2-dimensional Nuclear Magnetic Resonance (NMR)
spectroscopy, High-Resolution Electrospray Ionization Mass
Spectrometry (HRESIMS), Infrared Spectroscopy (IR) and
elemental analysis which confirmed the presence of the free base
form. The 1H-NMR and IR spectral were data were identical to
those of synthetic 4-MeO-PCP from the literature [11].
Ketamine and phencyclidine were from the NIMH-PDSP.
Chemical structures are shown in Figure 1.
Profiling Assays
Ki determinations, receptor binding profiles and functional
assays were provided by the National Institute of Mental Health’s
Psychoactive Drug Screening Program essentially as previously
described [12–16]; full methodological details are found on-line at:
http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf
In brief, compounds were initially screened in quadruplicate at a
fixed concentration of 10 mM. Compounds which yielded
inhibition of binding .50% were subjected to Ki determinations
via 12-point concentration-response studies in triplicate as
described [13] [17] and http://pdsp.med.unc.edu/UNC-
CH%20Protocol%20Book.pdf. All compounds were screened
against the targets listed in Table 1.
Results
A total of 6 compounds (ketamine, PCP, methoxetamine, 3-
MeO-PCP, 4-MeO-PCP and, 3-MeO-PCE; chemical structures in
Figure 1, were screened at 57 molecular targets relevant to CNS
drug action (Table 1) in quadruplicate at 10 mM via radioligand
binding assays. Where initial screening results disclosed significant
inhibitory activity (.50% inhibitory activity), Ki determinations
were performed as previously detailed. Representative Ki value
determinations are summarized in Table 2. Figure 2 shows a
summary of the final pKi data in a three dimensional mesh plot
format (see Table S1 for Ki values) while Figure 3 displays a
1Certificates of Analysis for these materials are available from the Logical
Standards website www.logical-standards.com
Table 1. Molecular Targets Profiled.
Serotonin Receptors 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT5, 5-HT6, 5-HT7
Dopamine Receptors D1, D2, D3, D4, D5
Glutamate Receptors NMDA Receptor (MK-801 binding site), mGluR5
GABA Receptors GABA-A, GABA-B, Benzodiazepine site on GABA-A, Peripheral Benzodiazepine Receptor
Biogenic Amine Transporters SERT, NET, DAT
Adrenoceptors a1A, a 1B, a 1D, a 2A, a 2B, a 2C. ß1, ß 2, ß 3
Muscarinic Receptors M1, M2, M3, M4, M5
Cannabinoid CB-1, CB-2
Nicotinic receptors a2 ß2; a2 ß4; a3 ß2; a3 ß4; a4 ß2; a4 ß2 functional assays; a4 ß4
Opioid Receptors MOR, KOR, DOR
Sigma Receptors Sigma1, Sigma2
Histamine Receptors H1, H2. H3, H4
doi:10.1371/journal.pone.0059334.t001
Figure 1. Chemical structures of ketamine, methoxetamine,
phencyclidine and analogues.
doi:10.1371/journal.pone.0059334.g001
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Table 2. Representative pKi values for ketamine, PCP and analogues.
Compound
NMDA pKi +/2 SD
(Ki, nM)
SERT pKi +/2 SD
(Ki, nM)
NET pKi +/2 SD
(Ki, nM)
Sigma1 pKi +/2 SD
(Ki, nM)
Sigma2 pKi +/2 SD
(Ki, nM)
Ketamine 6.1860.07 (659) 2 2 2 2
Phencyclidine 7.2360.07 (59) 5.6560.05 (2234) 2 2 6.8260.09 (136)
Methoxetamine 6.5960.06 (259) 6.3260.05 (481) 2 2 2
4-MeO-PCP 6.3960.06 (404) 6.0760.05 (844) 6.160.1 (713) 6.560.1 (296) 7.9360.08 (143)
3-MeO-PCP 7.6960.08 (20) 6.760.1 (216) 2 7.460.1 (42) 2
3-MeO-PCE 7.2260.08 (61) 6.960.06 (115) 2 5.360.1 (4519) 6.3160.1 (525)
Open boxes with – indicate that compounds failed the Primary Screen criterion of .50% inhibition at 10 mM.
Abbreviations: NMDA (N-methyl-D-aspartate receptor); SERT (serotonin transporter); NET (norepinephrine transporter).
doi:10.1371/journal.pone.0059334.t002
Figure 2. Mesh plot summarizing pharmacology of 3 novel PCP analogues. Shown in three dimensional mesh plot format are the pKi values
of the three novel PCP analogues (3-MeO-PCE, 3-MeO-phencyclidine and 4-MeO-phencyclidine; 1, 2 and 3 respectively) against a panel of 56
molecular targets.
doi:10.1371/journal.pone.0059334.g002
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representative dose-response curve for methoxetamine compared
with the reference compound MK-801 (dizocilpine).
Discussion
The results obtained in receptor screening reveal that the novel
analogues share the profile of ketamine and PCP as ligands for the
glutamate NMDA receptor. Although one previous study reported
that a number of ketamine and PCP analogues, including 4-MeO-
PCP, were active as NMDA receptor antagonists, using both
GluN2A and GluN2B receptor subtypes, this study did not include
methoxetamine or the 3-MeO-PCP and 3-MeO-PCE analogues
[18]. The present screening approach cannot distinguish between
NMDA receptor subtypes, but did reveal methoxetamine to have
an affinity for the NMDA receptor comparable to or higher than
the parent compound ketamine. The methoxy analogues of PCP
also had appreciable affinities for the NMDA receptor, and 3-
MeO-PCP in particular proved particularly active, with a Ki of
20 nM placing it among the most potent known NMDA
antagonists (cf MK-801 Ki= 4.8 nM).
Some indications of the relationship between chemical structure
and function can be discerned. Thus, methoxetamine is ketamine
without the 2-chloro but with a ‘3-methoxyl’ group on the phenyl
ring and with an N-ethyl rather than N-methyl substituent, whilst
3-MeO-phencyclidine is phencyclidine with a 3-methoxyl substit-
uent on the phenyl ring. The addition of the 3-methoxyl moiety to
the phenyl ring thus appears to enhance the affinity for the
serotonin transporter.
A potential role for glutamatergic mechanisms in schizophrenia
was first proposed based on the observation that psychotomimetic
drugs such as PCP and ketamine induce psychotic symptoms and
neurocognitive disturbances similar to those of schizophrenia by
blocking glutamate actions at NMDA receptors [19,20,21] [5].
While previous reports have implicated the dopamine transporter
(DAT) and sigma receptors in the behavioural pharmacology of
ketamine and PCP analogues [22–23], the present findings do not
support these suggestions. Nishimura et al [22] found only weak
effects of ketamine isomers on rat brain DAT (Ki = 50–390 mM)
while Chaudieu et al [23] reported submicromolar potency for
PCP and some related analogues. However, in the present study
no appreciable affinity was observed for any compound at a
concentration of ,10 mM for hDAT in binding assays. The poor
correlation with the results of Chaudieu et al [23] likely reflects the
fact that the substrate can bind to different sites on the transporter
than the radioligands used for displacement assays. Although PCP,
methoxetamine and the PCP analogues had appreciable affinity
for the sigma receptors (Table 1), (Table 1), ketamine had no
significant effect on either sigma-1 or sigma2 receptors when tested
at 10 mM, suggesting that while interactions with these receptors
might contribute to the profile of some dissociative anaesthetics,
this is not a common property which all share. Similarly, while
methoxetamine, 4-MeO-PCP and 3-MeO-PCE displayed sub-
micromolar affinities for the serotonin transporter (SERT), this is
not a universal property of these drugs.
Other publications have described a variety of other synthetic
analogues of ketamine and PCP, so it is likely that many other
chemical analogues of this family of drugs will be found to possess
the characteristic dissociative anaesthetic properties of ketamine
and PCP [18,23,24,25] [26]. These results imply that abuse of
these ketamine and PCP analogues could be associated with
significant psychiatric sequelae. On the other hand, analogues of
ketamine are also of pharmaceutical interest, following the
discovery of the rapid antidepressant properties of ketamine [27].
Supporting Information
Table S1 Ki values for ketamine, methoxetamine,
phencyclidine and analogues.
(XLSX)
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